Markets市場MTNB

BTIG terminates $50 million ATM sales agreement with Matinas BioPharma (MTNB)

Against the backdrop of a capital environment that continues to test smaller biotech issuers, BTIG, LLC terminated its at-the-market sales arrangement with Matinas BioPharma Holdings, Inc.

By Selene Vasquez·July 25, 2026·二〇二六年七月二十五日·2 min read

Source · 來源

sec.gov

Share · 分享

X in f w

← Back to the News Desk Filed · Markets

Related Dispatches

相關報導

News Desk →

01Markets市場
Snowflake surges 24% as tech premarket splits on AI delivery versus AI promise
Technology premarket trading carved a clear divide between companies delivering AI revenue now and those projecting it later.…
September 3, 2026 · 2 min
02Markets市場
Nvidia lifts AI infrastructure stocks as most Magnificent Seven slip in premarket
The capex cycle running through AI infrastructure pulled sharply away from the broader technology complex in premarket trading,…
August 27, 2026 · 2 min
03Markets市場
Wall Street falls after inflation data, Nvidia earnings next in view
Fresh inflation figures steered Wall Street indices lower as investors repositioned ahead of the upcoming earnings report from…
August 26, 2026 · 2 min

Elsewhere on the Desk

All Dispatches →

Crypto加密

Bitcoin above $80,000 as Fed rate-hike odds split ahead of September 16 decision

September 5, 2026 · 2 min

Deals

Miniso shares hit lowest since November 2022 as overseas profit margins collapse

September 5, 2026 · 2 min

Deals

BPOPO sets September dividend at USD 0.132813 per share

September 5, 2026 · 2 min

Crypto加密

Kraken Robotics stock trades 55% below its March high as integration risk and lumpy revenue cloud the near-term picture

September 5, 2026 · 2 min